New Data Demonstrate Aimovig ™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies

Aimovig Reduced Monthly Migraine Days for Patients With Chronic Migraine and Prior Treatment Failure, a Population With Significant Unmet Need Results From New Dedicated Cardiovascular Study Support Overall Safety Profile Observed in Aimovig Clinical Study Program Aimovig is the Only Investigational Biologic Product Specifically Designed to Prevent Migraine by Blocking the CGRP Receptor, Which is Associated With Migraine Activation THOUSAND OAKS, Calif., Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy of Aimovig™* (erenumab) for migraine prevention. Aimovig is the first and only ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news